Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corp. operated as a commercial-stage biopharmaceutical company developing and commercializing vaccines, with recurring announcements centered on its marketed products, pipeline and corporate status. The company commercialized HEPLISAV-B® vaccine, a hepatitis B vaccine approved in the U.S., European Union and United Kingdom for adults, and CpG 1018® adjuvant, which is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines.
Recurring updates include HEPLISAV-B revenue and financial results, share repurchase authorizations, investor conference presentations, licensing and collaboration activity, and clinical disclosures for vaccine candidates such as Z-1018 for shingles. Coverage also includes governance changes, material agreements, shareholder voting matters, capital-structure disclosures and public-company status updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.